Stock Analysis, Dividends, Split History

S / Sprint Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)25,753.11
Enterprise Value ($M)62,044.11
Book Value ($M)27,893.00
Book Value / Share6.86
Price / Book0.92
NCAV ($M)-45,109.00
NCAV / Share-11.09
Price / NCAV-0.57
Share Statistics
Common Shares Outstanding 4,011,474,569
Common Stock Shares Outstanding 4,000,000,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.09
Return on Equity (ROE)0.39
Balance Sheet (mrq) ($M)
Quick Ratio1.10
Current Ratio1.15
Income Statement (mra) ($M)
Spectrum Hosting Revenue0.00
Segment Reporting Information Total Net Operating Revenues32,439,000,000.00
Sales Revenue Services Net23,834,000,000.00
Operating Income2,727.00
Net Income7,389.00
Earnings Per Share Basic1.85
Earnings Per Share Diluted1.81
Cash Flow Statement (mra) ($M)
Cash From Operations10,062.00
Cash from Investing-6,135.00
Cash from Financing-6,135.00
Identifiers and Descriptors
Central Index Key (CIK)101830
Related CUSIPS
85207U905 85207U955

Split History

Stock splits are used by Sprint Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Telefonica Brasil accelerates content push with Tidal deal

9h reuters
SAO PAULO, Sept 19 (Reuters) - Telefonica Brasil SA has signed a partnership deal with music streaming app Tidal, Brazil’s largest telecoms firm said on Wednesday as it continues to expand its content offerings. (34-0)

5 Stocks to Buy Amid a Prolonged Trade War Slump

18h investorplace
Yesterday, President Donald Trump announced a new round of tariffs on Chinese goods — $200 billion to be exact. In response, China issued a $60 billion levy on U.S. goods. In an increasingly global economy, prospects for a trade war with China tend to foster nervousness among investors. (49-0)

Sprint (S) Unveils Wireless Protection Plan Sprint Complete

2018-09-17 zacks
Sprint Corporation (S - Free Report) recently introduced a protection plan, Sprint Complete. The company’s new protection plan offers wireless protection, enhanced repair service as well as technology support for select smartphones, tablets and smartwatches. (34-1)

5 5G Stocks to Buy That Will Stream Higher Profits for Investors

2018-09-14 investorplace
As telcos launch the first of the 5G networks, 5G stocks will become a focus. The technology will change wireless. How much speed it will add has become a point of controversy. Estimates from a few years ago predicted the improvement at 1,000 times 4G. (54-4)

Telecom Stock Roundup: Verizon 5G Internet Service, Ericsson-T-Mobile 5G Deal & More

2018-09-13 zacks
In the past five trading days, the uptrend in telecom stocks continued driven by healthy job growth data exhibiting signs of a strengthening economy. The stocks were also fueled by optimism from a U.S. proposal to initiate talks with China in the near future to iron out the trade-related differences between the two countries. Per the U.S. Labor Department report, about 201,000 new jobs were created in August, marking the 95th straight month of employment gains in the country. (41-0)

CUSIP: 85207U105